Status
Conditions
Treatments
About
Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire.
Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).
Deeper knowledge of Adverse Events during routine administration.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
980 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal